Evidence map›Paper›PMID 25119036›Full record

ArticleNature2014

Required enhancer-matrin-3 network interactions for a homeodomain transcription program.

Dorota Skowronska-Krawczyk, Qi Ma, Michal Schwartz, Kathleen Scully, Wenbo Li, Zhijie Liu, Havilah Taylor, Jessica Tollkuhn, Kenneth A Ohgi, Dimple Notani and 3 more

Abstract read
In one paragraph

Article in Nature, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. FOXO1 regulates expression of Neurod4 in the pituitary gland.Molecular and cellular endocrinology · 2024
    Article
  14. ImprintedeLife · 2023
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Dorota Skowronska-KrawczykHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Qi MaHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Michal Schwartz1] Howard Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA [2] The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, 5290002, Israel.
Kathleen ScullyHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Wenbo LiHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Zhijie LiuHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Havilah TaylorHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Jessica TollkuhnHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Kenneth A OhgiHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Dimple NotaniHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
Yoshinori KohwiLawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
Terumi Kohwi-ShigematsuLawrence Berkeley National Laboratory, Berkeley, California 94720, USA.
Michael G RosenfeldHoward Hughes Medical Institute, Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, California 92093, USA.
University of California, San Diego · USLawrence Berkeley National Laboratory · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9M
Transcriptional Genomics CoreP01DK074868 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2007 to 2016
$16.6M
HORMONAL AND DEVELOPMENTAL REGULATION OF GENE EXPRESSIONR01DK018477 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1986 to 2025
$12.7M
REGULATION OF NEUROENDOCRINE SWITCHING EVENTSR37DK039949 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1987 to 2020
$12.3M
Studies on gene regulation by chromatin organizationR37CA039681 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KOHWI-SHIGEMATSU, TERUMI · 2002 to 2015
$9.8M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Ligand Regulated Epigenetic/Nuclear Architectural Strategies and Human DiseaseR01NS034934 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1995 to 2013
$6.8M
Enhancer TherapyR01CA173903 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2012 to 2016
$6.3M
MOLECULAR MECHANISMS OF AORTIC AND PULMONARY DEFECTSR01HL065445 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 2000 to 2014
$5.3M
REGULATION OF NEUROENDOCRINE SWITCHING EVENTSR01DK039949 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 1996 to 2024
$2.4M
Genome-wide location analysis of neuronal genesR01NS048243 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROSENFELD, MICHAEL G · 2005 to 2007
$903k
Howard Hughes Medical InstituteNCI NIH HHS CA173903NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA173903NCI NIH HHS R37 CA039681NHLBI NIH HHS HL065445NHLBI NIH HHS R01 HL065445NIDDK NIH HHS DK018477NIDDK NIH HHS DK039949NIDDK NIH HHS P01 DK074868NIDDK NIH HHS R01 DK018477NIDDK NIH HHS R37 DK039949NINDS NIH HHS NS034934NINDS NIH HHS P30 NS047101NINDS NIH HHS R01 NS034934NINDS NIH HHS R01 NS048243
6 · The paper itself

Abstract

Homeodomain proteins, described 30 years ago, exert essential roles in development as regulators of target gene expression; however, the molecular mechanisms underlying transcriptional activity of homeodomain factors remain poorly understood. Here investigation of a developmentally required POU-homeodomain transcription factor, Pit1 (also known as Pou1f1), has revealed that, unexpectedly, binding of Pit1-occupied enhancers to a nuclear matrin-3-rich network/architecture is a key event in effective activation of the Pit1-regulated enhancer/coding gene transcriptional program. Pit1 association with Satb1 (ref. 8) and β-catenin is required for this tethering event. A naturally occurring, dominant negative, point mutation in human PIT1(R271W), causing combined pituitary hormone deficiency, results in loss of Pit1 association with β-catenin and Satb1 and therefore the matrin-3-rich network, blocking Pit1-dependent enhancer/coding target gene activation. This defective activation can be rescued by artificial tethering of the mutant R271W Pit1 protein to the matrin-3 network, bypassing the pre-requisite association with β-catenin and Satb1 otherwise required. The matrin-3 network-tethered R271W Pit1 mutant, but not the untethered protein, restores Pit1-dependent activation of the enhancers and recruitment of co-activators, exemplified by p300, causing both enhancer RNA transcription and target gene activation. These studies have thus revealed an unanticipated homeodomain factor/β-catenin/Satb1-dependent localization of target gene regulatory enhancer regions to a subnuclear architectural structure that serves as an underlying mechanism by which an enhancer-bound homeodomain factor effectively activates developmental gene transcriptional programs.

Indexed as

Gene Expression Regulation, DevelopmentalTranscription, GeneticAnimalsbeta CateninCells, CulturedEnhancer Elements, GeneticHomeodomain ProteinsHumansMatrix Attachment Region Binding ProteinsMiceNuclear Matrix-Associated ProteinsPituitary GlandProtein BindingRNA-Binding ProteinsTranscription Factor Pit-1beta CateninHomeodomain Proteinsmatrin-3 protein, mouseMatrix Attachment Region Binding ProteinsNuclear Matrix-Associated ProteinsPOU1F1 protein, humanPou1f1 protein, mouseRNA-Binding ProteinsSatb1 protein, mouseTranscription Factor Pit-1

Identifiers

PMID25119036
PMCPMC4358797
OpenAlexW2010289839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.